Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...
In a recent study published in Cell, researchers described their self-designed chimeric receptor-binding domain (RBD)-dimer vaccine approach to adapt severe acute respiratory syndrome coronavirus 2 ...
A preliminary study by researchers from the Garvan Institute of Medical Research and the University of New South Wales and published on the preprint server bioRxiv* in June 2020 reports the use of ...
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma Between 2009 and 2015, we administered 46 CAR T-cell treatments to 43 patients (ClinicalTrials.gov identifier: NCT00924326).
Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics is strengthening its commitment to Environmental, Social, and Governance (ESG) principles by aligning with the UN’s ...
Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics, a leading Australian cell therapy company, has appointed Dr. Rebecca McQualter as its new CEO, signaling a strategic ...
Creating a functional lung using interspecies chimeric animals is an attractive albeit challenging option for lung transplantation, requiring more research on the viable conditions needed for organ ...
A team of researchers has reported for the first time the live birth of a monkey that contains a high proportion of cells derived from a monkey stem cell line. This 'chimeric' monkey is composed of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results